{{priceData.date}} {{priceData.time}}
{{'2025-05-12T06:01:36Z' | dateFormatFilter}}
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
{{'2025-05-07T05:30:45Z' | dateFormatFilter}}
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
{{'2025-05-06T12:00:11Z' | dateFormatFilter}}
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.